Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches

Area of Science:

• Oncology
• Molecular Biology
• Proteomics

Background:

• KRAS mutations are prevalent in human cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
• Targeting KRAS, particularly the KRAS^G12C variant, has shown promise but faces challenges due to resistance.
• Understanding proteomic alterations is crucial for overcoming therapeutic resistance.

Purpose of the Study:

• To review current knowledge on proteomic alterations driven by oncogenic KRAS mutations.
• To focus on allele-specific proteome signatures and the role of KRAS post-translational modifications (PTMs).
• To discuss emerging resistance mechanisms from a proteomics-informed perspective.

Main Methods:

• Comprehensive profiling of proteomic alterations associated with KRAS mutations.
• Analysis of KRAS interactome, signaling pathways, and cellular processes.
• Review of recent therapeutic advances and resistance mechanisms.

Main Results:

• KRAS mutations lead to significant proteomic changes, affecting cellular networks and contributing to tumorigenesis.
• Allele-specific proteome signatures and PTMs of KRAS play key roles in modulating protein function.
• Proteomics offers insights into intrinsic and acquired resistance to KRAS-targeted therapies.

Conclusions:

• Proteomic studies are vital for understanding KRAS-driven tumorigenesis and resistance.
• Targeting KRAS variants requires a deep understanding of associated proteomic landscapes.
• Future therapeutic strategies should leverage proteomics to overcome resistance and improve patient outcomes.